Firdapse
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.firdapse.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Firdapse
Catalyst Pharmaceuticals, Inc. specializes in developing and providing FIRDAPSE® (amifampridine), the first-line therapy for patients with Lambert-Eaton myasthenic syndrome (LEMS). This FDA-approved medication is clinically proven to help maintain muscle strength and mobility in patients aged six and older. The company also offers personalized support and financial services through Catalyst Pathways to assist FIRDAPSE patients. Their services are intended for individuals living with LEMS and healthcare professionals seeking effective treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Firdapse your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Firdapse
Firdapse, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Firdapse has new funding data
Check out if Firdapse is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Firdapse has recently received funding, and reach out quickly before it becomes old news!
Click to see if Firdapse had a recent Job posting/layoffs
Earning: See what the market has to say on Firdapse recently announced quarterly report
Product Launch: Get notified when Firdapse launches new products
Recommended Actions
Find VP level buyers at Firdapse
Find 2 more new buyers
Compare Similar Companies to Firdapse
Compare insights from companies similar to Firdapse, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Firdapse
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Firdapse is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Firdapse is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Firdapse.
Firdapse Tech Stack
A closer look at the technologies used by Firdapse
Firdapse News & Media
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035How Catalyst's Patent Settlement With Lupin Reshapes FIRDAPSE's Investment Outlook at CPRX
Earlier this week, Catalyst Pharmaceuticals announced it reached a settlement with Lupin Pharmaceuticals to resolve patent litigation over FIRDAPSE, permitting Lupin to launch a generic version no earlier than February 25, 2035, pending FDA approval. This agreement concludes all current patent disputes between Catalyst, SERB S.A., and Lupin in the U.S., following similar deals with Teva and Inventia, and shapes expectations for future competition around FIRDAPSE. We will explore how the...Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lamber
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Firdapse
Sign Up For FreeTo access detailed company insights
Catalyst Pharmaceuticals, Inc. specializes in developing and providing FIRDAPSE® (amifampridine), the first-line therapy for patients with Lambert-Eaton myasthenic syndrome (LEMS). This FDA-approved medication is clinically proven to help maintain muscle strength and mobility in patients aged six and older. The company also offers personalized supp... Read More
